Robert G. Price

Statistics

Publications

Citations

1.8K

H-Index

Active since

1994

Affiliations

Research Triangle Park Foundation(Current)

Age UK

GlaxoSmithKline (United States)

GlaxoSmithKline (United Kingdom)

Inserm

Robert G. Price is an author at Research Triangle Park Foundation specializing in severe asthma treatment, asthma pharmacotherapy, and asthma management.

ORCID

Publications per year

1994–2024

Publications

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Sumita Khatri, Wendy C. Moore, Peter G. Gibson et al. · Journal of Allergy and Clinical Immunology · 2018 · 300 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

Njira Lugogo, Christian Domingo, Pascal Chanez et al. · Clinical Therapeutics · 2016 · 278 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Sandhya Khurana, Guy Brusselle, Elisabeth H. Bel et al. · Clinical Therapeutics · 2019 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Kenneth R. Chapman, Frank C. Albers, Bradley E. Chipps et al. · Allergy · 2019 · 159 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Ian Pavord, Frances Gardiner, Liam G. Heaney et al. · Frontiers in Immunology · 2023 · 118 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +15

1–5 of 19